Tackling the EpiPen Pricing Controversy
Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News. Read the full article here.
Network Meta-Analysis Needed to Improve Clinical Oncology Value Framework
In his letter to the editor published in the Journal of Clinical Oncology, IVI’s Evidence Synthesis Expert, Jeroen Jansen, argues that network meta-analysis is the only transparent framework to help answer the treatment selection question. Responding to his letter, members of the ASCO Task Force reply that Dr. Jansen makes a “strong argument for the use […]
Discussing A Model for More Rational Drug Prices
IVI Executive Director, Darius Lakdawalla, is featured in the AP’s Big Story, discussing the need for a more rational drug pricing model. Read the full article here.
Responding to President Obama on the Affordable Care Act
Amitabh Chandra and co-author Jonathan Skinner respond to President Obama’s JAMA letter describing the success of the Affordable Care Act (ACA), concluding that, while the landmark legislation suffers from a number of fundamental problems, it is also “far more moderate, innovative — and difficult to replace — than its critics claim.” Read the full article […]
How New Value Frameworks Can Undermine the Ability of Patients and Providers to Find the Best Treatment
In Tomas Philipson’s latest Forbes.com op-ed, he and co-author Jason Shafrin (IVI Director of Research) describe the potential for new value frameworks to undermine the ability of patients and providers to find the best treatment for a specific patient. Read the full article here.
Rapid Biomedical Innovation Calls for Similar Innovation In Pricing and Value Measurement
Advances in foundational science, technology, and clinical knowledge are driving a revolution in patient care. At the same time, spending on these innovative drugs and devices has increased dramatically. The question is, what—if anything—should be done to regulate this innovation? To balance physician prescribing of state-of-the-art drugs and patient desires to access them with the […]
Discussing the Problems with Adding Budget Criteria to Value Assessments
In a recent post on the IVI-sponsored Health Affairs blog series, Darius Lakdawalla, Executive Director of IVI, and Peter Neumann discuss the use of explicit budget impact criteria in value assessment. Lakdawalla and Neumann write that budgetary concerns are understandable, given that healthcare decision makers are faced with limited resources. Linking short-term budget criteria to assessments of […]
Regulatory, Legal Uncertainties are Barriers to Value-Based Agreements
Alison Sexton Ward, Mark Linthicum, Michelle Drozd, Alison Silverstein, and Joe Vandigo identify key legal and regulatory barriers in the creation of value-based contracts for drugs in their recent addition to the IVI-sponsored Health Affairs blog series. Based on two-part, in-depth interviews with a group of five stakeholders regarding their experience with value-based agreements, the authors identify […]
Divorcing Reimbursement From Real-World Prices
In a recent post on the IVI-sponsored Health Affairs blog series, David Tawes and Marta Wosinka examine consequences of the disconnection between market prices and reimbursement, specifically in that Medicare still uses 2003 average wholesale prices (AWPs) for some drugs. Tawes and Wosinka point out that, in the case of drugs where the actual costs […]
21st Century Cures Legislation a Bad Deal for Patients
In a recent post on the IVI-sponsored Health Affairs blog series, Ameet Sarpatwari and Michael Sinha discuss why the 21st Century Cures legislation increases risk of patient harm. Among the issues they highlight are uncertainty around funding — especially for prevention, research, and regulatory science — and the loosening of evidence standards for FDA approvals. […]